Literature DB >> 34161467

Prevalence of premalignant and malignant skin lesions in oculocutaneous albinism patients.

Andréia Nogueira Ramos1, João Gabriel Rosa Ramos2, Juliana Dumet Fernandes3.   

Abstract

OBJECTIVE: Oculocutaneous albinism describes a group of pigmentary disorders that lead to skin sensitivity and predisposition to skin malignances. AIMS: To analyze clinical and epidemiological data in oculocutaneous albinism patients and to determine the prevalence of malignant skin lesions, assessing possible risk factors for skin cancer.
METHODS: Cross-sectional study evaluating epidemiological data, habits of sun exposure and sun protection, and clinical examination of albino patients followed in a reference dermatology outpatient clinic in Brasil. Our primary outcome was the occurrence of malignant skin lesions in biopsied tissues.
RESULTS: Of 74 patients analyzed, 11 (15%) had one or more suspicious lesions and were biopsied, of which 8 (72.7%) patients presented with basal cell carcinomas, 7 (63.3%) presented with squamous cell carcinoma, and 1 (9%) presented with melanoma. Moreover, 32(43%) patients presented with actinic keratosis. Age, female gender, previous history of sunburn, history of malignant lesions and history of sun exposure without photoprotection were associated with the presence of malignant lesions. LIMITATIONS: Unicentric, non-aleatory sample.
CONCLUSIONS: There was a high prevalence of malignant and pre-malignant lesions in this population. Some potentially modifiable risk factors were associated with the occurrence of malignant skin lesions.

Entities:  

Year:  2021        PMID: 34161467     DOI: 10.1590/1806-9282.67.01.20200356

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.209


  1 in total

1.  Dermatologic manifestations in patients with the Hermansky-Pudlak syndrome types 1 and 3.

Authors:  Gabriel Santos Malave; Natalio J Izquierdo; Nestor P Sanchez
Journal:  Orphanet J Rare Dis       Date:  2022-07-30       Impact factor: 4.303

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.